Hsbc Holdings PLC Makes New Investment in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• HSBC Holdings PLC acquired 13,850 shares of Arrowhead Pharmaceuticals during the 1st quarter, valued at approximately $173,000.
• Multiple institutional investors increased their stakes in Arrowhead Pharmaceuticals, with 62.61% of the stock now owned by institutional investors and hedge funds.
• Analysts have mixed ratings on Arrowhead Pharmaceuticals, with a consensus rating of "Buy" and an average price target of $43.14, following recent stock performance and earnings results.

Hsbc Holdings PLC purchased a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,850 shares of the biotechnology company's stock, valued at approximately $173,000.

Other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC boosted its position in Arrowhead Pharmaceuticals by 297.6% during the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 1,628 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $49,000. CWM LLC boosted its position in Arrowhead Pharmaceuticals by 134.3% during the first quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 2,523 shares during the last quarter. KBC Group NV boosted its position in Arrowhead Pharmaceuticals by 40.8% during the first quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock valued at $94,000 after purchasing an additional 2,132 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in Arrowhead Pharmaceuticals during the first quarter valued at approximately $133,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 15,000 shares of the firm's stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $25.00, for a total transaction of $375,000.00. Following the transaction, the insider owned 247,122 shares in the company, valued at $6,178,050. This trade represents a 5.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders sold 25,000 shares of company stock worth $575,000. 4.30% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ ARWR traded down $1.91 during trading hours on Monday, reaching $27.17. 3,267,510 shares of the stock were exchanged, compared to its average volume of 2,920,812. The firm has a market capitalization of $3.76 billion, a price-to-earnings ratio of -21.23 and a beta of 1.00. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $29.34. The stock's fifty day simple moving average is $19.00 and its 200 day simple moving average is $16.24.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to the consensus estimate of $29.01 million. During the same quarter in the prior year, the business posted ($1.38) EPS. Sell-side analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ARWR. B. Riley raised Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, August 11th. Wall Street Zen cut Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. TD Cowen raised Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, July 28th. Chardan Capital reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 11th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, September 2nd. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $43.14.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.